Long-Term (156-Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of 3 Phase III, Randomized, Controlled Trials
Mease PJ, Gladman DD, Gomez-Reino JJ, Hall S, Kavanaugh A, Lespessailles E, Schett G, Shah K, Teng L, Wollenhaupt J (2016)
Publication Type: Conference contribution
Publication year: 2016
Journal
Book Volume: 68
Authors with CRIS profile
Involved external institutions
Celgene Corporation
United States (USA) (US)
Swedish Medical Center
United States (USA) (US)
Schön Klinik Hamburg Eilbek
Germany (DE)
University of Orléans / Université d'Orléans
France (FR)
University of Toronto
Canada (CA)
Complejo Hospitalario Universitario de Santiago de Compostela
Spain (ES)
Monash University
Australia (AU)
University of California, San Diego
United States (USA) (US)
United States (USA) (US)
Swedish Medical Center
United States (USA) (US)
Schön Klinik Hamburg Eilbek
Germany (DE)
University of Orléans / Université d'Orléans
France (FR)
University of Toronto
Canada (CA)
Complejo Hospitalario Universitario de Santiago de Compostela
Spain (ES)
Monash University
Australia (AU)
University of California, San Diego
United States (USA) (US)
How to cite
APA:
Mease, P.J., Gladman, D.D., Gomez-Reino, J.J., Hall, S., Kavanaugh, A., Lespessailles, E.,... Wollenhaupt, J. (2016). Long-Term (156-Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of 3 Phase III, Randomized, Controlled Trials.
MLA:
Mease, Philip J., et al. "Long-Term (156-Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of 3 Phase III, Randomized, Controlled Trials." 2016.
BibTeX: Download